TY - JOUR AU - Ahn, Myung-Ju PY - 2018 TI - Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer JF - Journal of Thoracic Disease; Vol 10, No 3 (March 31, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Stage III non-small cell lung cancer (NSCLC) accounts for one-third of NSCLC patients. Stage IIIA is considered resectable, but most of stage IIIA/B patients are unresectable, leading to chemoradiotherapy being standard of care. The median overall survival remains poor with less than 15% of 5-year overall survival after chemoradiotherapy. UR - https://jtd.amegroups.org/article/view/19733